PubMed Health⌕ Search

PubMed · 3878166

Prostatic cancer: some epidemiological features.

Abstract

Prostatic cancer is a frequent tumour in old men. The disease is very common in North America, particularly among Blacks, and in Scandinavia, while it is currently rare in Asian countries. Both morbidity and mortality rates have increased in most areas in recent years, the rate of increase being greatest in populations where the risk has hitherto been low. "Latent" (microscopic) prostatic cancer is much commoner than overt clinical prostatic cancer and, in contrast to the latter, the prevalence is similar in a wide spectrum of countries and ethnic groups. Detection of these latent tumours is dependent on medical care variables. The relationships between tumor development, latency and progression are not understood. It may be useful to consider "latent" prostatic cancer as a separate entity in future classifications and epidemiological research. Hormonal, sexual, dietary, chemical and genetic factors have been implicated in the aetiology although the mechanisms by which they act and the relationships between these factors are not known. As a high fat diet has been found to increase risk in case-control studies, a plausible sequence of events would be a fat-induced change of hormone profile with increased uptake by the prostate of male sex hormones leading to carcinoma--as in the rat. The evidence is however by no means entirely consistent and should be explored further in studies of the US Black and White populations, populations with age-standardized incidence rates in the order of 100 and 50 per 100,000 per annum respectively. If it be accepted that the factors leading to latent carcinoma of prostate are evenly distributed throughout the world, then studies directed at uncovering the agents responsible for progression from latent to clinically invasive state could be rewarding. Such studies would need to be large, prospective in nature and would require a high frequency of autopsy of cohort members to ascertain whether the prostate was cancer free or not. Prevention is not feasible on the basis of current knowledge and further inquiry regarding the aetiopathogenesis of prostatic cancer is needed before preventive approaches can be envisaged.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A S Donn, C S Muir. 1985. Prostatic cancer: some epidemiological features.. https://pubmed.ncbi.nlm.nih.gov/3878166/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The case for routine use of adjuvant therapy in pancreatic cancer.

Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long-term survival. Even with optimal surgical management, 5-year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy.

Adenocarcinoma↗

Proposal for a new definition of true cardia carcinoma.

BACKGROUND AND OBJECTIVES: It remains controversial whether cardia carcinoma should be categorized and treated as esophageal cancer or gastric cancer. The purpose of this study was to develop a reasonable definition of cardia carcinoma. METHODS: Patients with Siewert type II carcinomas were divided into two subgroups: 25 patients with a tumor center within 1 cm of the esophagogastric junction (EGJ) (type IIA) and 22 patients with tumor center 1-2 cm aboral of the EGJ (type IIB). Patients with subcardia carcinomas, 40 with invasion to the EGJ (type III) and 110 without (type IIIe-), were used as controls. RESULTS: The patients with type IIB carcinomas showed no different characteristics from those with type III or type IIIe- carcinomas, except for the stage of the disease. On the other hand, those with type IIA carcinomas were associated with a higher male/female ratio, higher incidences of elevated appearance, differentiated histology, and mediastinal node metastasis, and a significantly lower survival rate as compared with patients with subcardia carcinomas. Multivariate survival analysis revealed that type IIA is a significant prognostic determinant, but that type IIB is not. CONCLUSION: Type IIA carcinomas should be treated as true cardia carcinoma; type IIB as subcardia carcinoma. Our results should be confirmed by a prospective study.

Adenocarcinoma↗

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.

BACKGROUND: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal. The purpose of this study was to review our recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery. STUDY DESIGN: The outcomes of 37 patients with LMGC who underwent hepatectomy between 1990 and 2005 were assessed. No extrahepatic distant metastasis and feasibility of macroscopic curative resection were requisite indications for surgery. The prognostic values of clinicopathological factors were assessed by univariate and multivariate analyses. RESULTS: There was no in-hospital mortality. The median survival time and overall 5-year survival rate after hepatectomy of the patients with LMGC were 31 months and 11%, respectively. Intrahepatic recurrence following hepatectomy was found in 23 patients (62%). Variables independently associated with poor survival were bilobar metastasis (P = 0.002, CI = 1.9-16.3) and a maximum tumor diameter of >or= 4 cm (P = 0.006, CI = 1.4-7.7). The depth of the primary tumor and the timing of metastasis were not associated with survival. CONCLUSIONS: Surgical resection for LMGC may be indicated in patients with unilobar metastasis and/or tumors less than 4 cm in diameter. Synchronous metastasis is not a contraindication for hepatectomy.

Adenocarcinoma↗